[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
IJRR Information::
About the Journal
Editorial Board
Keywords
For Authors::
Aims and Scope
Call for Papers
Submission Instructions
For Reviewers::
Referee page
Subscription::
Subscription Form
News & Events::
Journal News
Web Mail::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
ISSN
Hard Copy 2322-3243
Online 2345-4229
..
Online Submission
Now you can send your articles to IJRR office using the article submission system.
..

AWT IMAGE

AWT IMAGE
Volume 23, Issue 3 (7-2025)                   Int J Radiat Res 2025, 23(3): 627-633 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Zhao W, Liu Y, Li X, Chen G. The synergistic role of ultrasound-guided interventions and radiotherapy in hepatocellular carcinoma: A meta-analysis of treatment outcomes. Int J Radiat Res 2025; 23 (3) :627-633
URL: http://ijrr.com/article-1-6592-en.html
The synergistic role of ultrasound-guided interventions and radiotherapy in hepatocellular carcinoma: A meta-analysis of treatment outcomes
W. Zhao , Y. Liu , X. Li , G. Chen
Department of Ultrasound, Minda Hospital of Hubei Minzu University, Enshi, Hubei, China 445000 , 819136262@qq.com
Abstract:   (412 Views)
Background: To assess the effectiveness and safety of combining ultrasound-guided interventional therapy with radiotherapy (RT) in treating Hepatocellular Carcinoma (HCC). Materials and Methods: Literature was searched in PubMed, Coghlan's database and Web of Science (WOS) up to November 2024 without language restriction. Outcome indicators included complete response (CR), partial response (PR), stable disease (SD), disease progression (PD), 1-year survival rate, and adverse events (AEs). The Cochrane Collaboration tool was utilized to evaluate the risk of bias in the included studies. Statistical analysis was performed based on revman software, and P<0.05 was considered statistically significant. Results: Five studies were included in the analysis, and the overall quality of the studies was high. The combination therapy group demonstrated statistically significant differences compared to the control group in PR (OR=2.14, 95% CI: 1.32–3.48, P=0.002), PD (OR=0.45, 95% CI: 0.27–0.76, P=0.003), and AEs (OR=0.54, 95% CI: 0.35–0.82, P=0.004). No statistically significant differences were observed between the two groups in terms of CR (OR=1.31, 95% CI: 0.24–7.01, P=0.760), SD (OR=0.88, 95% CI: 0.50–1.55, P=0.670), and one-year survival rate (OR=1.62, 95% CI: 0.85–3.09, P=0.140). Conclusion: Ultrasound-guided interventional therapy combined with RT demonstrates certain clinical advantages in the treatment of HCC, particularly in improving PR, reducing PD, and managing AEs. Additional studies are required to confirm its long-term effectiveness and safety.
Keywords: Hepatocellular carcinoma, ultrasound-guided, radiotherapy, synergistic treatment, meta-analysis.
Full-Text [PDF 1308 kb]   (125 Downloads)    
Type of Study: Original Research | Subject: Radiation Biology
References
1. 1. Li H, Qin S, Liu Y, et al. (2021) Camrelizumab combined with FOLFOX4 regimen as first-line therapy for advanced hepatocellular carcinomas: a sub-cohort of a multicenter phase Ib/II study. Drug Design, Development and Therapy, 15: 1873-1882. [DOI:10.2147/DDDT.S304857]
2. Chen W, Mao Y, Liu C, et al. (2021) Exosome in Hepatocellular Carcinoma: an update. Journal of Cancer, 12: 2526-2536. [DOI:10.7150/jca.54566]
3. Nakharutai N, Chitapanarux I, Traisathit P, et al. (2023) Prediction of survival and analysis of prognostic factors for hepatocellular carcinoma: a 20-year of imaging diagnosis in Upper Northern Thailand. BMC cancer, 23: 1063. [DOI:10.1186/s12885-023-11429-6]
4. Papadakos SP, Machairas N, Stergiou IE, et al. (2023) Unveiling the Yin-Yang balance of M1 and M2 macrophages in hepatocellular carcinoma: role of exosomes in tumor microenvironment and immune modulation. Cells, 12(16): 2036. [DOI:10.3390/cells12162036]
5. Jia W, Han Y, Mao X, et al. (2022) Nanotechnology strategies for hepatocellular carcinoma diagnosis and treatment. RSC Advances, 12: 31068-31082. [DOI:10.1039/D2RA05127C]
6. Liu C, Fan H, Guan L, et al. (2021) In vivo and in vitro efficacy of crocin against Echinococcus multilocularis. Parasites & Vectors, 14: 364. [DOI:10.1186/s13071-021-04866-4]
7. Xin X, Cheng X, Zeng F, et al. (2024) The role of TGF-β/SMAD signaling in hepatocellular carcinoma: from mechanism to therapy and prognosis. Int J Biol Sci, 20: 1436-1451. [DOI:10.7150/ijbs.89568]
8. White DL, Thrift AP, Kanwal F, et al. (2017) Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012. Gastroenterology, 152: 812-820.e815. [DOI:10.1053/j.gastro.2016.11.020]
9. Yang L, Yan C, Wang J (2022) Effect of multi-disciplinary team care program on quality of life, anxiety, and depression in hepatocellular carcinoma patients after surgery: A randomized, controlled study. Frontiers in Surgery, 9: 1045003. [DOI:10.3389/fsurg.2022.1045003]
10. Zeng S, Wang Z, Zhu Q, et al. (2023) Identification of risk and prognostic factors for intrahepatic vascular invasion in patients with hepatocellular carcinoma: a population-based study. Translational Cancer Research, 12: 93-112. [DOI:10.21037/tcr-22-1912]
11. Hatooka M, Kawaoka T, Aikata H, et al. (2018) Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial. BMC Cancer, 18: 633. [DOI:10.1186/s12885-018-4519-y]
12. Yao M, Ma M, Xu H, et al. (2018) Small PLGA nanocapsules Co-encapsulating copper sulfide nanodots and fluorocarbon compound for photoacoustic imaging-guided HIFU synergistic therapy. RSC Advances, 8: 4514-4524. [DOI:10.1039/C7RA12074E]
13. Hui TC, Kwan J, Pua U (2021) Advanced techniques in the percutaneous ablation of liver tumors. Diagnostics (Basel), 11(4): 585. [DOI:10.3390/diagnostics11040585]
14. Yang P and Li N (2022) Efficacy of percutaneous ethanol injection versus radiofrequency ablation for single hepatocellular carcinoma no larger than 5 cm. J Int Med Res, 50: 3000605221111281. [DOI:10.1177/03000605221111281]
15. Qiu J, Cheng Z, Jiang Z, et al. (2024) Immunomodulatory precision: A narrative review exploring the critical role of immune checkpoint inhibitors in cancer treatment. Int J Mol Sci, 25 (10): 5490. [DOI:10.3390/ijms25105490]
16. Venkatesulu BP and Krishnan S (2018) Radiosensitization by inhibiting DNA repair: Turning the spotlight on homologous recombination. Hepatology, 67: 470-472. [DOI:10.1002/hep.29526]
17. Ke Q, Su X, Zhou S, et al. (2011) Efficacy analysis of ultrasound-guided high-intensity focused ultrasound combined with 3D conformal radiotherapy for the treatment of primary liver cancer. Practical Journal of Cancer, 26: 184-187.
18. Ding L, Zhang Z, Jiang G (2016) Short- and long-term efficacy of ultrasound-guided radiofrequency ablation combined with conformal radiotherapy for liver cancer. Modern Oncology, 24(01): 88-91.
19. Li T (2014) Efficacy analysis of high-intensity focused ultrasound combined with 3D conformal radiotherapy for the treatment of primary liver cancer. Chinese Community Physicians, 30(17): 67-69.
20. Wang L, Li L, Wang X, et al. (2018) Comparison of combination stereotactic body radiotherapy plus high-intensity focused ultrasound ablation versus stereotactic body radiotherapy alone for massive hepatocellular carcinoma. Medical Science Monitor, 24: 8298-8305. [DOI:10.12659/MSM.910735]
21. Zhou L, Du T, Zhu X (2015) Clinical study of high-intensity focused ultrasound combined with intensity-modulated radiotherapy for the treatment of advanced liver cancer. Journal of Difficult and Complicated Diseases, 14: 1255-1258.
22. Fujita N, Kanogawa N, Makishima H, et al. (2022) Carbon-ion radiotherapy versus radiofrequency ablation as initial treatment for early-stage hepatocellular carcinoma. Hepatology Research, 52: 1060-1071. [DOI:10.1111/hepr.13827]
23. Yang K, Lee JE, Park W, et al. (2023) Recent trends in radiotherapy use for major cancers in Korea. Jpn J Clin Oncol 53, 1177-1182. [DOI:10.1093/jjco/hyad106]
24. Loi M, Comito T, Franzese C et al. (2021) Stereotactic body radiotherapy in hepatocellular carcinoma: patient selection and predictors of outcome and toxicity. J Cancer Res Clin Oncol, 147: 927-936. [DOI:10.1007/s00432-020-03389-2]
25. Gharzai LA, Wang C, Tang M, et al. (2023) Efficacy of a Second course of radiation for patients with metachronous hepatocellular carcinoma. Practical Radiation Oncology, 13: e504-e514. [DOI:10.1016/j.prro.2023.05.008]
26. Hayashi K, Suzuki O, Wakisaka Y, et al. (2024) Prognostic analysis of radiation-induced liver damage following carbon-ion radiotherapy for hepatocellular carcinoma. Radiation Oncology, 19: 51. [DOI:10.1186/s13014-024-02444-3]
27. Xu Z, Hu Y, Huang L (2024) Effectiveness and safety of radiofrequency ablation versus liver resection in the treatment of early-stage hepatocellular carcinoma: A systematic review and meta-analysis. Annali Italiani di Chirurgia, 95: 109-118. [DOI:10.62713/aic.3155]
28. Li LQ, Su TS, Wu QY, et al. (2023) Therapeutic Outcome of Stereotactic Body Radiotherapy for Small Hepatocellular Carcinoma Lesions - A Systematic Review and Network Meta-analysis. Clinical oncology (Royal College of Radiologists (Great Britain)) 35, 652-664. [DOI:10.1016/j.clon.2023.07.002]
29. Yang GY, He ZW, Tang YC et al. (2024) Unraveling the efficacy network: A network meta-analysis of adjuvant external beam radiation therapy methods after hepatectomy. World Journal of Gastrointestinal Surgery, 16: 205-214. [DOI:10.4240/wjgs.v16.i1.205]
30. Li J, Zhu C, Yue P, et al. (2021) Identification of glycolysis related pathways in pancreatic adenocarcinoma and liver hepatocellular carcinoma based on TCGA and GEO datasets. Cancer Cell Int, 21: 128. [DOI:10.1186/s12935-021-01809-y]
31. Terzi E, Golfieri R, Piscaglia F, et al. (2012) Response rate and clinical outcome of HCC after first and repeated cTACE performed "on demand". J Hepatol, 57: 1258-1267. [DOI:10.1016/j.jhep.2012.07.025]
32. Wang X, Chen M, Wei R, et al. (2019) External radiation versus internal radiation for patients with advanced unresectable HCC -A SEER based study. Journal of Cancer, 10: 1171-1180. [DOI:10.7150/jca.28983]
33. Otgontuya A, Jeng CJ, Wu TN, et al. (2023) Comparison of the treatment efficacies of HIFU, HIFU combined with GnRH-a, and HIFU combined with GnRH-a and LNG-IUS for adenomyosis: A systematic review and meta-analysis. Taiwanese Journal of Obstetrics & Gynecology, 62: 226-238. [DOI:10.1016/j.tjog.2022.11.009]
34. Mee SF, Polan DF, Dewaraja YK, et al. (2023) Stereotactic body radiation therapy (SBRT) following Yttrium-90 ((90)Y) selective internal radiation therapy (SIRT): a feasibility planning study using (90)Y delivered dose. Phys Med Biol, 68(6): 065003. [DOI:10.1088/1361-6560/acbbb5]
35. Koonce NA, Chen X, Moros EG, et al. (2015) PET and MRI-guided focused ultrasound surgery for hypoxic-tissue ablation combined with radiotherapy in solid tumor. International Journal of Radiation Research, 13: 1-12.
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
International Journal of Radiation Research
Persian site map - English site map - Created in 0.07 seconds with 48 queries by YEKTAWEB 4722